Top Industry Leaders in the Vulvar Cancer Market
Roche Holding AG Received FDA approval for their FoundationOne CDx assay, a comprehensive genomic profiling test, to guide personalized treatment decisions in vulvar cancer patients.
Guardant Health Expanded their liquid biopsy testing platform to include vulvar cancer, allowing for non-invasive tumor profiling and potentially improving treatment planning.
Myriad Genetics Developed a new genetic test panel specifically for vulvar cancer, offering a more comprehensive analysis of potential genetic risk factors and personalized treatment options.
Boston Scientific Corporation Launched a new vaginal dilator specifically designed for vulvar cancer survivors, addressing a critical need for post-treatment recovery and intimacy support.
Hologic Introduced their Aptimaยฎ HPV test with improved sensitivity for detecting HPV strains associated with vulvar cancer, contributing to earlier diagnosis and prevention efforts.
List of Vulvar Cancer Key Companies in the Market
- Amgen Inc. (US)
- Bristol-Myers Squibb Company (US)
- Celgene Corporation (US)
- Eli Lilly and Company (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Merck & Co.Inc. (US)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Sanofi (France)
- and Johnson & Johnson Services Inc. (US)